TY - JOUR
T1 - Simple preparation and purification of ethanol-free solutions of 3'-deoxy-3'-[ 18F]fluorothymidine by means of disposable solid-phase extraction cartridges
AU - Pascali, Claudio
AU - Bogni, Anna
AU - Fugazza, Lorenza
AU - Cucchi, Claudio
AU - Crispu, Ornella
AU - Laera, Luca
AU - Iwata, Ren
AU - Maiocchi, Greta
AU - Crippa, Flavio
AU - Bombardieri, Emilio
PY - 2012/5
Y1 - 2012/5
N2 - Introduction: 3'-Deoxy-3'-[ 18F]fluorothymidine ([ 18F]FLT) shows great potential as a tracer for proliferative studies with PET. However, its regular application is often limited by low radiochemical yields and the use of a troublesome HPLC separation. Moreover, a high content of ethanol, at least one-fold higher than the European Pharmacopoeia and US Pharmacopoeia's established limit, is always present in the final product. The present study reports an optimization of the reaction conditions and a simple and straightforward purification step which affords a solution of [ 18F]FLT suitable for human use. Methods: Several conditions and materials were tested for both the nucleophilic substitution and purification step. The latter was achieved by means of a series of commercial solid-phase extraction cartridges. Very conveniently, the whole one-pot synthesis was carried out on commercial automated modules using basically the same setup employed for the synthesis of [ 18F]FDG. Results: Under routine conditions, radiochemical yields of 37% [decay-corrected to start of synthesis (SOS)] were achieved in ca. 39 min from SOS, with radiochemical purities >98% (usually >99%). The negligible radiolysis observed could be easily suppressed by adding 0.5% of EtOH. Typical unlabelled chemical impurities detected were thymidine (0.15 ppm), thymine (0.28 ppm) and stavudine (0.05 ppm). Conclusions: A reliable, simple and efficient preparation of [ 18F]FLT has been developed, able to afford an ethanol-free solution of the tracer with no need for any HPLC purification. Because of its similarity to the [ 18F]FDG synthesis, the method can be readily implemented on basically all the commercial modules developed for this common radiotracer.
AB - Introduction: 3'-Deoxy-3'-[ 18F]fluorothymidine ([ 18F]FLT) shows great potential as a tracer for proliferative studies with PET. However, its regular application is often limited by low radiochemical yields and the use of a troublesome HPLC separation. Moreover, a high content of ethanol, at least one-fold higher than the European Pharmacopoeia and US Pharmacopoeia's established limit, is always present in the final product. The present study reports an optimization of the reaction conditions and a simple and straightforward purification step which affords a solution of [ 18F]FLT suitable for human use. Methods: Several conditions and materials were tested for both the nucleophilic substitution and purification step. The latter was achieved by means of a series of commercial solid-phase extraction cartridges. Very conveniently, the whole one-pot synthesis was carried out on commercial automated modules using basically the same setup employed for the synthesis of [ 18F]FDG. Results: Under routine conditions, radiochemical yields of 37% [decay-corrected to start of synthesis (SOS)] were achieved in ca. 39 min from SOS, with radiochemical purities >98% (usually >99%). The negligible radiolysis observed could be easily suppressed by adding 0.5% of EtOH. Typical unlabelled chemical impurities detected were thymidine (0.15 ppm), thymine (0.28 ppm) and stavudine (0.05 ppm). Conclusions: A reliable, simple and efficient preparation of [ 18F]FLT has been developed, able to afford an ethanol-free solution of the tracer with no need for any HPLC purification. Because of its similarity to the [ 18F]FDG synthesis, the method can be readily implemented on basically all the commercial modules developed for this common radiotracer.
KW - [ F]FLT
KW - Automation
KW - Fluorothymidine
KW - PET tracer
KW - SPE cartridge purification
UR - http://www.scopus.com/inward/record.url?scp=84860341315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860341315&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2011.10.005
DO - 10.1016/j.nucmedbio.2011.10.005
M3 - Article
C2 - 22172390
AN - SCOPUS:84860341315
SN - 0969-8051
VL - 39
SP - 540
EP - 550
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 4
ER -